MYCN in Neuroblastoma: “Old Wine into New Wineskins”
MYCN Proto-Oncogene, BHLH Transcription Factor (MYCN) has been one of the most studied genes in neuroblastoma. It is known for its oncogenetic mechanisms, as well as its role in the prognosis of the disease and it is considered one of the prominent targets for neuroblastoma therapy. In the present w...
Main Authors: | Maria Braoudaki, Kyriaki Hatziagapiou, Apostolos Zaravinos, George I. Lambrou |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-10-01
|
Series: | Diseases |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-9721/9/4/78 |
Similar Items
-
Epigenetic Dysregulation in <i>MYCN</i>-Amplified Neuroblastoma
by: Soraya Epp, et al.
Published: (2023-12-01) -
Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy
by: Anders Valind, et al.
Published: (2023-12-01) -
MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma
by: Prasoon Agarwal, et al.
Published: (2023-05-01) -
Increased Efficacy of Histone Methyltransferase G9a Inhibitors Against MYCN-Amplified Neuroblastoma
by: Jacob Bellamy, et al.
Published: (2020-05-01) -
Identification of a Five-Gene Signature Derived From MYCN Amplification and Establishment of a Nomogram for Predicting the Prognosis of Neuroblastoma
by: Yuren Xia, et al.
Published: (2021-12-01)